Global sales of $2.5 billion forecast for Zolgensma by 2025

Swiss pharma giant Novartis (NOVN: VX) recently announced new anticipated long-term positive data for its one-time infusion gene therapy, Zolgensma (onasemnogene abeparvovec-xioi), which is set to help the drug generate global sales of $2.5 billion by 2025 and lead the spinal muscular atrophy (SMA) market, says data and analytics company GlobalData.

The data showed significant therapeutic benefit in patients with SMA over a range of extended studies, covering patients treated pre-symptomatically, and sustained durability in patients up to five years post-dosing. Interim results were also reported of an intrathecal formulation testing in older patients with SMA type 2 aged two to five.

Sarah Elsayed, pharma analyst at GlobalData, commented: “The robust overall trial results are expected to spur the drug's sales, expand its future patient pool and further dispel controversies raised over the drug’s credibility after its pre-clinical data manipulation incident and $2.1 million price tag.’’